The short answer: Not always. In 2023 the American Society of Anesthesiologists (ASA) advised holding weekly GLP-1 drugs like Mounjaro for one week before an elective procedure. In 2024 five societies, including the ASA, revised that advice. Most patients can now continue Mounjaro if they have no stomach symptoms, often with a 24-hour liquid diet instead. Your anesthesiologist makes the final call, so tell them you take tirzepatide as early as you can.

What do the guidelines say right now?

Two documents matter, and the newer one wins.

The first is the ASA consensus guidance from June 2023. It told anesthesiologists to consider holding daily GLP-1 drugs on the day of surgery. For weekly drugs, the advice was to hold the dose a week before the procedure. The ASA applied this to every indication, every dose, and every type of procedure.

The second is the multi-society clinical practice guidance published in October 2024. The American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and SAGES approved it. The ASA affirmed its value in May 2024. Its position is different:

  • The decision should come from shared decision-making between you, the surgical team, the anesthesia team, and your prescriber.
  • GLP-1 drugs may be continued before surgery in patients without elevated risk of delayed gastric emptying.
  • A liquid diet for at least 24 hours before the procedure can lower aspiration risk when there is concern.
  • If the team does decide to hold the drug, they should follow the original ASA timing: one week for weekly drugs.
  • Everyone still gets screened for stomach symptoms on the day of the procedure.

The 2024 document names the factors that raise risk: the dose escalation phase, higher doses, weekly dosing, current GI symptoms, and conditions that slow the stomach, such as gastroparesis or Parkinson's disease. Mounjaro is a weekly drug, so it meets one factor by default.

Why does Mounjaro matter for anesthesia?

Mounjaro slows how fast food leaves your stomach. The FDA label carries a specific warning. It says there have been rare postmarketing reports of pulmonary aspiration in patients on GLP-1 drugs who had general anesthesia or deep sedation. Those patients had food still in the stomach even though they said they had fasted as instructed.

Aspiration means stomach contents enter the lungs while you are unconscious. A slowed stomach can defeat normal fasting rules.

The data on retained stomach contents are consistent. A 2024 review in the Journal of Clinical Endocrinology and Metabolism summarized the largest study, which covered 35,183 upper endoscopies. Among 922 GLP-1 users, 13.6% had retained gastric contents versus 2.3% of non-users, a 4-fold difference. A 2025 study of 1,368 outpatient upper endoscopies found the same pattern: 14.1% of GLP-1 users had retained contents versus 3.8% of non-users.

The same review adds a caveat: retained contents are common, but actual aspiration is rare. The 2025 study found no rise in adverse outcomes despite more retained food.

How long does tirzepatide stay in your body?

The FDA label lists a half-life of approximately 5 days for tirzepatide. Steady state takes 4 weeks of weekly dosing. A one-week hold removes only part of the drug. After 7 days, roughly a third to a half of the dose is still in your blood.

Two other label facts help. First, the label says the delay in gastric emptying is largest after the first dose and diminishes over time. The ASA guidance and the JCEM review both call this tachyphylaxis. If you have been on a stable dose for months, your stomach has likely adapted more than a new user's has. Second, the label says a missed dose can be taken within 4 days (96 hours). After that, skip it and resume on the regular day. Our missed dose guide walks through that rule.

Because the drug lingers, the 2024 multi-society group admitted that the correct hold duration is unknown. That is one reason the guidance shifted toward diet changes and day-of screening instead of blanket holds.

What should you tell your surgeon or anesthesiologist?

The 2024 guidance says risk assessment should happen with enough time before surgery to adjust the plan. Tell them at the first pre-op visit, not on the morning of surgery.

Bring these details:

  1. The drug name (Mounjaro, tirzepatide) and your current dose.
  2. The date of your last injection and your usual injection day.
  3. Whether you are still increasing the dose or on a stable maintenance dose. The dosing schedule explains why this matters.
  4. Any nausea, vomiting, bloating, reflux, constipation, or abdominal pain in the past week.
  5. Why you take it: type 2 diabetes, weight management, or both.

Then ask three questions. Should I hold my next dose, and when? Should I follow a liquid diet the day before? What happens if I feel nauseated that morning? The ASA guidance says GI symptoms on the day of surgery may delay the case. The 2024 group says the team can also use rapid sequence induction, which protects the airway faster, rather than cancel.

Get ongoing side effects under control before you schedule. Our guide to managing side effects covers the common ones.

What about a colonoscopy or upper endoscopy?

In November 2023 the AGA published a rapid clinical practice update as a direct response to the ASA. The AGA press release put it plainly: there was no data to support all patients stopping GLP-1 drugs before elective endoscopy. Patients who fasted normally (no food for 8 hours, no liquids for 2 hours) and had no nausea, vomiting, dyspepsia, or bloating could proceed. A liquid diet one day before could replace stopping the drug.

Colonoscopy adds a separate concern: bowel prep quality. Three studies point the same direction.

There is one piece of good news. The 2025 upper endoscopy study found that patients who did a bowel prep for a same-day colonoscopy had far less retained stomach content (odds ratio 0.157). The clear liquid diet that comes with prep seems to protect the stomach too. Ask your GI office whether you need a longer clear liquid diet. For general prep guidance, see colonoscopy.md.

What if you take Mounjaro for diabetes and need to hold it?

Holding the drug is not free if you take it for type 2 diabetes. The 2023 ASA guidance said that if a GLP-1 drug for diabetes is held longer than its dosing interval, the team should consider an endocrinologist for bridging therapy to avoid hyperglycemia.

The 2024 multi-society document went further. It said any decision to hold must be balanced against the surgical and medical risk of a hazardous metabolic state like hyperglycemia. Bridging therapy can be costly, hard to arrange, and can cause hypoglycemia. In practice:

  • Loop in your prescribing doctor before you hold a dose.
  • Ask whether you need a temporary plan for glucose control during the hold.
  • Check your glucose more often in the days before and after the procedure.

If you take Mounjaro for weight alone, a short hold carries less metabolic risk. The 2024 group specifically warned against holding the drug only because the indication is obesity, which it called weight bias.

The bottom line

You do not automatically have to stop Mounjaro before surgery or endoscopy. The 2023 ASA advice was a one-week hold for weekly drugs. The 2024 multi-society guidance replaced that with an individual assessment. Most patients without stomach symptoms can continue, often with a 24-hour liquid diet. Tirzepatide's 5-day half-life means a one-week hold does not clear it anyway. Tell the surgical and anesthesia teams early, report any nausea or bloating, and follow their plan. If you take Mounjaro for diabetes, involve your prescriber before you skip a dose.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Do not stop, hold, or restart Mounjaro before a procedure without instructions from your surgeon, anesthesiologist, or prescribing clinician.